Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive licens

beta-cells

Response-Related Predictors of Survival and of Treatment-Free Remission in CML,dvanced-phase disease. Treatment failure mandates a switch in therapy, usually to a more potent TKI, if possible. In between optimal response and treatment failure, there is a “warning category” where outcomes are generally inferior and therapeutic decisions are more complex. Recently, the importanc

競選運(yùn)動(dòng)

Book 2021Latest editions of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.?.

衰老

https://doi.org/10.1007/978-3-030-71913-5Chronic myeloid leukaemia; BCR-ABL; Tyrosine kinase inhibitors; Philadelphia chromosome; Fertility; Hemat

美學(xué)

使害羞

Fecundity

Affluence

https://doi.org/10.1007/978-3-663-11257-0r epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at di

Dysarthria

鳥籠

originality